301130SZSE

Review Opinion of the Compensation and Assessment Committee of Jilin Province Xidian Pharmaceutical Technology Development Co., Ltd. on the 2026 Restricted Stock Incentive Plan

✨ AI Summary

The Compensation and Assessment Committee of Jilin Province Xidian Pharmaceutical Technology Development Co., Ltd. has reviewed the 2026 Restricted Stock Incentive Plan. The review confirms compliance with relevant laws and regulations, and the eligibility of incentive recipients. The plan aims to enhance the company's incentive mechanism, attract talent, and align interests among shareholders, the company, and core team members.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· azure_openai

Review Opinion of the Compensation and Assessment Committee

The Compensation and Assessment Committee of Jilin Province Xidian Pharmaceutical Technology Development Co., Ltd. (hereinafter referred to as "the Company") has conducted a review of the "2026 Restricted Stock Incentive Plan (Draft)" (hereinafter referred to as "the Incentive Plan (Draft)") in accordance with the provisions of the Company Law of the People's Republic of China (hereinafter referred to as "the Company Law"), the Securities Law of the People's Republic of China (hereinafter referred to as "the Securities Law"), the Administrative Measures for Equity Incentives of Listed Companies (hereinafter referred to as "the Management Measures"), and the Articles of Association of Jilin Province Xidian Pharmaceutical Technology Development Co., Ltd. (hereinafter referred to as "the Articles of Association"). The relevant circumstances and review opinions are as follows:

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.